Podcast CME Course Information
Exam: Exam 447: High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Issue: October 22, 2019
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Upon completion of this podcast, participants will be able to understand that individuals with a negative amyloid PET scan and positive plasma Aβ42/Aβ40 are at increased risk for converting to amyloid PET-positive. Plasma Aβ42/Aβ40 could be used in prevention trials to screen for individuals likely to be amyloid PET-positive and at risk for Alzheimer disease dementia.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
- Patient Care
- Medical Knowledge
Program Accreditations Subcommittee (PAS) is responsible for reviewing and evaluating all CME programs. Joseph F. Kass, MD, JD, FAAN, has received personal compensation for activities as an expert witness in litigation and in an editorial capacity for the American Academy of Neurology. Barney J. Stern, MD, FAAN, has received personal compensation for book chapter contributions. The other members of the committee (Samir Belagaje, MD; J. Clay Goodman, MD, FAAN; Omotola A. Hope, MD; Shannon M. Kilgore, MD, FAAN) and AAN staff (Kristine Mitchell) report no disclosures. Robert A. Gross, MD, PhD, FAAN, has received funding for travel and/or speaker honoraria from the American Academy of Neurology; receives a stipend as Editor-in-Chief of Neurology; has received consultant fees from GlaxoSmithKline and Harris Interactive; has served on speakers' bureaus for Abbott, UCB, and GlaxoSmithKline; has conducted clinical trials over the past 5 years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus, but has ceased participation in industry-sponsored clinical trials and speakers' bureaus since his appointment as Neurology EIC in 2010; and has received research support from the Department of the Army, UCBPharma, and University of Rochester Medical Center/NIH. Dr. Stacey Clardy serves as Podcast Editor for Neurology® and has received research support forWestern Institute for Biomedical Research (WIBR). Dr. Jeff Ratliff serves as Podcast Deputy Editor for Neurology andreceived a speaker honorarium from Haverford College. AAN staff members editing the test (P Baskin, L Kleffman, K Aman Ramm) have no disclosures. The CME Journal Editors who have reviewed the exam are James WM Owens Jr., MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology and Adam Kelly, MD, who has served as Guest Editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.
Dr. Randall Bateman has served on the scientific advisory boards for the Alzheimer’s Disease Cooperative Study, National Alzheimer’s Disease Neuroimaging Initiative Industry Scientific Advisory Board Amyloid-? Subteam member, Roche, Merck, and Pfizer; has received speaker funding or travel honoraria from Salk Institute for Biological Studies, the Rainwater Foundation, Alzheimer's Disease International, Alzheimer’s Association, Merck, FBRI, Janssen, International Conference on Molecular Neurodegeneration, Pfizer, Roche, AC Immune, MIT, American Neurological Association, and Japanese Society for Neuroscience; has served on the editorial boards for Alzheimer's Research and Therapy and The Journal for the Prevention of Alzheimer Disease; holds various patents; has been employed by Washington University School of Medicine, A4, Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU), and Dominantly Inherited Alzheimer's Network (DIAN); has served as a consultant for Roche, Merck, Pfizer, Johnson & Johnson, AC Immune, and Eisai; has received commercial research support from Eli Lilly, Roche, Janssen, DIAN Pharmaceutical Consortium, Abbvie, Avid, Biogen, and Centene; has received governmental research support from the NIH; has received foundation/society research support from BrightFocus Foundation, Cure Alzheimer's Fund, Association for Frontotemporal Degeneration, Rainwater Foundation, Alzheimer's Association, GHR Foundation, and an anonymous foundation; holds stock options for C2N Diagnostics; has received license fee payments from C2N Diagnostics; and has received royalty payments from C2N Diagnostics. Dr. Jeffrey Burns serves as the Deputy Editor for Neurology Podcast; has served on the Data and Safety Monitoring board for NIH-funded trials; has received travel honoraria from Astra-Zeneca; has served on the editorial board of Journal of Alzheimer's Disease; has served as a consultant for protocol development for Stage 2 Innovations in 2017 and 2018; has received commercial research support from Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, vTv Therapeutics, Janssen, and Roche; has received governmental research support from NIH; and has served as an expert witness or consultant in legal proceedings. Dr. Jason Crowell serves as an editor for the Neurology Podcast. Dr. Stanley B. Prusiner has served on the scientific advisory boards for ViewPoint Therapeutics and New Ventures Funds; serves on the editorial boards for Discovery Medicine, JAMA Neurology, and Prion; holds a patent for modified cell line and method of determining tauopathies; has received publishing royalties for Madness and Memory (Yale University Press) and Prion Biology and Prion Diseases (Cold Spring Harbor Laboratory Press); has received commercial research support from Daiichi Sankyo; has received governmental research support from NIH Degenerative and Dementing Diseases of Aging; has received academic research support from Brockman Foundation, Henry M. Jackson Foundation, and Sherman Fairchild Foundation; has received foundation/society research support from Hillblom Foundation, G. Harold and Leila Y. Mathers Charitable Foundation, Sherman Fairchild Foundation, John Douglas French Alzheimer’s Foundation, Schott Foundation for Public Education, Lincy Foundation, and Rainwater Charitable Foundation; holds Board of Directors compensation from Trizell, Ltd.; and has held stock/stock options for medical equipment & materials as a member of the scientific advisory boards for ViewPoint Therapeutics and New Ventures Funds.
The other participants report no disclosures.
CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.
The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit™
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Neurology holds copyright for all materials in this exam.
Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.
Hardware and Software Requirements
A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.
For More Information
Executive Editor, Neurology®